You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Conditions:   Stem Cell Transplantation;   Leukemia;   Lymphoma
Interventions:   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin (ATG);   Drug: G-CSF (Filgrastim);   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mesna
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting
Body: Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Duke University
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Immunodeficiencies;   Anemia
Interventions:   Drug: TBI, Thiotepa, Cyclophosphamide, ATG;   Drug: Busulfan, Melphalan, Rabbit ATG;   Drug: Busulfan, Fludarabine, Alemtuzumab;   Drug: Busulfan, Fludarabine, Rabbit ATG;   Drug: Fludarabine, Cyclophosphamide, ATG;   Drug: Busulfan, Cyclosphosphamide, Rabbit ATG,
Sponsor:   Columbia University
Terminated
Body: Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   RAEB-2;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified June 2017
Body: Condition:   Severe Osteopetrosis
Interventions:   Procedure: umbilical cord blood transplantation;   Drug: Campath-1H;   Radiation: Total Lymphoid Irradiation;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Procedure: marrow graft transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Unknown status
Body: Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia;   Hodgkins Lymphoma
Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified September 2017
Body: Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Suspended
Body: Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2017
Body: Conditions:   MDS;   Anemia, Aplastic;   Inborn Errors of Metabolism;   Congenital Marrow Failure;   Congenital Immunodeficiency Syndrome
Intervention:   Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors:   Joanne Kurtzberg, MD;   Aldagen
Completed - verified April 2017
Body: Conditions:   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Radiation: total marrow irradiation;   Procedure: umbilical cord blood transplantation;   Biological: Granulocyte colony-stimulating factor;   Biological: HLA-matched related donor bone marrow
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed - verified July 2017
Body: Conditions:   Hurler's Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Sphingolipidoses;   Krabbe Disease;   Wolman's Disease;   Niemann-Pick Disease Type B;   Niemann-Pick Disease, Type C
Interventions:   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Campath-1H;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Condition:   Osteopetrosis
Interventions:   Procedure: Stem Cell or Umbilical Cord Blood Transplantation;   Drug: Campath, Busulfan, Clofarabine;   Procedure: Total Lymphoid Irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Condition:   Fanconi Anemia
Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2017
Body: Condition:   Histiocytosis, Langerhans-cell
Interventions:   Biological: alemtuzumab;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: stem cell transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting

Pages